[China Cord Blood Corporation Announces Results of 2013 Annual General Meeting HONG KONG, China, December 17, 2013 - China Cord Blood Corporation At the Annual General Meeting, shareholders · ratified the appointment of KPMG as the independent auditors of the Company for the financial year ending March 31, 2014 and authorized any duly formed committee of the directors to fix]
[China Cord Blood Corporation Announces Results of 2013 Annual General Meeting HONG KONG, China, December 17, 2013 - China Cord Blood Corporation At the Annual General Meeting, shareholders · ratified the appointment of KPMG as the independent auditors of the Company for the financial year ending March 31, 2014 and authorized any duly formed committee of the directors to fix]
[ORM Pre-effective Amendment No. 1 to F REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Skystar Bio-Pharmaceutical Company Nevada 2834 33-0901534 (State or other jurisdiction (Primary Standard Industrial (I.R.S. Employer of incorporation or organization) Code Number) Identification Number) 4/F Building B Chuangye Square, No. 48 Keji Road, Gaoxin District Xi’an, Shaanxi Province, P.R. China (8629) 8819-3188 (Address, including zip code,] [Schiff Hardin LLP Letterhead [ December 16, 2013 Board of Directors Skystar Bio-Pharmaceutical Company 4/F Building B, Chuangye Square, No. 48 Keji Road, Gaoxin District, Xi’an, Shaanxi Province, P.R. China Re Registration Statement on Form S-3 Ladies and Gentlemen: Based on the foregoing and subject to the qualifications set forth below, we are of the opinion that, when any applicable] [[Emmel & Klegerman PC Letterhead] December 16, 2013 Skystar Bio-Pharmaceutical Company 4/F, Building B, Chuangye Square, No. 48 Keji Rd Gaoxin District, Xi’an, Shaanxi Province, P.R. China Ladies and Gentlemen: Skystar Bio-Pharmaceutical Company December 16, 2013 Page 2 In connection with this opinion letter, we have examined and relied upon copies of the following documents, together with such other documents]
[ORM Pre-effective Amendment No. 1 to F REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Skystar Bio-Pharmaceutical Company Nevada 2834 33-0901534 (State or other jurisdiction (Primary Standard Industrial (I.R.S. Employer of incorporation or organization) Code Number) Identification Number) 4/F Building B Chuangye Square, No. 48 Keji Road, Gaoxin District Xi’an, Shaanxi Province, P.R. China (8629) 8819-3188 (Address, including zip code,] [Schiff Hardin LLP Letterhead [ December 16, 2013 Board of Directors Skystar Bio-Pharmaceutical Company 4/F Building B, Chuangye Square, No. 48 Keji Road, Gaoxin District, Xi’an, Shaanxi Province, P.R. China Re Registration Statement on Form S-3 Ladies and Gentlemen: Based on the foregoing and subject to the qualifications set forth below, we are of the opinion that, when any applicable] [[Emmel & Klegerman PC Letterhead] December 16, 2013 Skystar Bio-Pharmaceutical Company 4/F, Building B, Chuangye Square, No. 48 Keji Rd Gaoxin District, Xi’an, Shaanxi Province, P.R. China Ladies and Gentlemen: Skystar Bio-Pharmaceutical Company December 16, 2013 Page 2 In connection with this opinion letter, we have examined and relied upon copies of the following documents, together with such other documents]
[LightInTheBox Holding Co., Ltd. Announces Share Repurchase Program Mr. Alan Guo, Chairman and CEO of LightInTheBox, commented, The implementation of our share repurchase program reflects the confidence that our Board and management have in LITBs growth prospects and operating fundamentals. This repurchase program reflects a commitment by our Board to enhance value for our shareholders while retaining adequate flexibility for]
[LightInTheBox Holding Co., Ltd. Announces Share Repurchase Program Mr. Alan Guo, Chairman and CEO of LightInTheBox, commented, The implementation of our share repurchase program reflects the confidence that our Board and management have in LITBs growth prospects and operating fundamentals. This repurchase program reflects a commitment by our Board to enhance value for our shareholders while retaining adequate flexibility for]
[Chinard Bloodrporation Announces Results of 2013 Annual General Meeting HONG KONG, China, December 17, 2013 - Chinard Bloodrporation At the Annual General Meeting, shareholders ratified the appointment of KPMG the independent auditors of thempany for the financial year ending March 31, 2014 and authorized any duly formedmmittee of the directors to fix the remuneration of]
[SCHEDULE 13G 58.Com Inc (Name of Issuer) Class A Common Stock (Title of Class of Securities) 31680Q104 (CUSIP Number) October 31, 2013 (Date of Event Which Requires Filing of this Statement) o Rule 13d-1(b) x Rule 13d-1(c) o Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with]
[ORM Pre-effective Amendment No. 1 to F REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933ystar Bio-Pharmaceuticalmpany Nevada 2834 33-0901534 (State or other jurisdiction (Primary Standard Industrial (I.R.S. Employer oforporation or organization)de Number) Identification Number) 4/F Building B Chuangye Square, No. 48 Keji Road, Gaoxin District Xian, Shaanxi Province, P.R. China] [Schiff Hardin Letterhead [ December 16, 2013 Board of Directorsystar Bio-Pharmaceuticalmpany 4/F Building B, Chuangye Square, No. 48 Keji Road, Gaoxin District, Xian, Shaanxi Province, P.R. China Re Registration Statement on Form S-3 Ladies and Gentlemen: Based on the foregoing and subject to the qualifications set forth below, we are of the opinion that, when] [[Emmel & Klegerman PC Letterhead] December 16, 2013ystar Bio-Pharmaceuticalmpany 4/F, Building B, Chuangye Square, No. 48 Keji Rd Gaoxin District, Xian, Shaanxi Province, P.R. China Ladies and Gentlemen:ystar Bio-Pharmaceuticalmpany December 16, 2013 Page 2 Innnection with this opinion letter, we have examined and relied uponpies of the following documents, together with such other documents we]
[ADVANCED SEMICONDUCTOR ENGINEERING, INC.]
